Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, Sor…

Extended-release injectable naltrexone for opioid use disorder: A systematic review. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Addiction. 2018 Feb 3. doi: 10.1111/add.14180. Abstract https://www.ncbi.nlm…

Naltrexone for Opioid Use Disorders: A Review. Source: CADTH Report / Project in Briefs [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011-. 2017 Aug. Excerpt: With the potential advantages of XR-NTX compared with…

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB. J Pain Res. 2018 Feb 8;11:301-311. doi: 10.2147…

Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD. J Psychiatry Neurosci. 2018 Feb 23;43(3…

Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Saxon AJ, Akerman SC, Liu CC, Sullivan MA, Silverman BL, Vocci FJ. Addiction. 2018 Mar 1. doi: 10.1111/add.14199…